Legal Representation
Attorney
Joi A. White
USPTO Deadlines
Application History
16 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 17, 2023 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Apr 17, 2023 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Sep 13, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jul 19, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jul 19, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jun 29, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jun 14, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 13, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 13, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 13, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 14, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Dec 14, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Dec 14, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 12, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 5, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 7, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Pharmaceutical and therapeutics research and development services; research and development in the therapeutics, pharmaceutical, biopharmaceutical, and biotechnology fields; research and product development in the field of human therapeutics; providing a website featuring research and development information in the therapeutics, pharmaceutical, biopharmaceutical and biotechnology fields; research services using a platform of biological research tools and techniques for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases, fibrotic diseases and infectious diseases with systemically delivered, locally active immune modulatory conjugates; pharmaceutical product development; conducting clinical trials for others; scientific research and development services; providing medical and scientific research information relating to pharmaceuticals, therapeutics, biopharmaceuticals and biotechnology
Additional Information
Design Mark
The mark consists of a thick diagonal line in light purple color intersecting another thick diagonal line in purple to form a stylized letter "V".
Color Claim
The color(s) light purple and purple is/are claimed as a feature of the mark.
Classification
International Classes
042